PRA Advances to Become PRA Health Sciences
The Future of Clinical Development Today
PRA, a leading clinical research organization, today announced that it has changed its name to PRA Health Sciences (PRA). The name change to PRA Health Sciences is the culmination of several strategic actions which support and enhance the company’s commitment to the future of clinical development.
Starting over 18 months ago, PRA strategically strengthened its coverage of China and created a joint venture with the leading clinical development firm in China, forming WuXiPRA. PRA then bolstered its capabilities in Russia and Eastern Europe by acquiring ClinStar, the premier provider of CRO services in Russia and Eastern Europe. With the subsequent acquisition of RPS, the pioneer of the Embedded Solutions™ model, PRA enhanced its ability to offer a more comprehensive breadth of services across all segments of the biopharmaceutical industry. At the close of 2013, PRA purchased CRI Lifetree, which augmented its existing Phase I and bioanalytical capabilities, cementing PRA as the most comprehensive, high-end Phase I organization in the world.
"The expansion of our global presence, the growth in our breadth of services, and the deepening of our capabilities we initiated over the last year-and-a-half enable us to better serve our clients," said Colin Shannon, president and CEO, PRA Health Sciences. "This change to our name reflects our historical roots as a scientifically rich company, the breadth and depth of our solutions, and most importantly, our dedication to working with sponsors to bring new treatments to market that will positively impact the lives of patients and their families.”
As one unified company with a broad range of specific expertise, PRA is well-equipped and intently focused on working to improve the lives of patients and providing innovative solutions that will drive the future of clinical development.
In addition to the new name, PRA is introducing a new website more reflective of the company today. This new interactive, website can be experienced at: www.prahs.com
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
